The association of CDC20 upregulation with TP53 null mutation or functional silencing was uncovered in aneuploid AML [37], which suggested CDC20 as a potential target and biomarker in TP53 mutant AML. The gene discussed is CDC20; the disease is acute myeloid leukemia.